Protazil (1.56% diclazuril) is the first and only alfalfa-based top-dress, antiprotozoal pellet indicated for the treatment of equine protozoal myeloencephalitis (EPM) caused by Sarcocystis neurona (S. neurona) in horses. Protazil is an easy-to-administer, alfalfa-based pellet containing 1.56 percent diclazuril that is fed as a top-dress on the horse’s daily grain ration. This formulation is designed to eliminate the tubes and mess clients face with other EPM treatment products. Each container of Protazil comes with an easy-to-read calibrated scoop, allowing for flexible dosing based on the weight of each individual horse.
Proven safe and efficacious
Protazil was proven safe in a field safety study of 214
privately owned horses of various genders, breeds and ages that tested
positive for EPM based on clinical examinations and positive Western
blot tests performed on the CSF. The horses were randomly assigned to
one of three treatment groups. Horses received 1, 5 or 10 mg/kg of
diclazuril as a top-dress for 28 days. Clinical evaluations and spinal
taps were performed by 10 independent investigators on days 0, 28 and
Adverse events were reported for two of the 214 horses evaluated
for safety. In the first case, a horse was enrolled showing severe
neurologic signs. Within 24 hours of dosing, the horse was recumbent,
biting, and exhibiting signs of dementia. The horse died, and no cause
of death was determined. In the second case, the horse began walking
stiffly approximately 13 days after the start of dosing. The referring
veterinarian reported that the horse had been fed grass clippings and
possibly had laminitis.
There was no difference in clinical outcome between the treatment
groups; therefore, the 42 horses that received the lowest dose (1 mg/kg
for 28 days) were evaluated for product efficacy. Based on the numbers
of horses that seroconverted to negative Western Blot status, and the
numbers of horses classified as successes by the clinical
investigators, 28 of 42 horses (67%) at 1 mg/kg were considered
successes. With regard to independent expert masked videotape
assessments, 10 of 24 horses (42%) at 1 mg/kg were considered
"EPM is a frustrating disease that continues to confound the
industry, but we’re continuing to make progress in understanding the
disease as well as finding new, innovative ways to help diagnose and
treat EPM," Vaala said. "Protazil is one example. It is a safe,
efficacious and hassle-free way to treat EPM."
Protazil is an alfalfa-based antiprotozoal pellet indicated for the treatment of EPM caused by S. neurona in horses. Protazil is labeled for a dosage rate of 1 mg/kg for 28 consecutive days.
Use of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets is
contraindicated in horses with known hypersensitivity to diclazuril.
For use in horses only. Do not use in horses intended for human
consumption. Not for human use. Keep out of reach of children.
The safe use of PROTAZIL® (1.56% diclazuril) Antiprotozoal Pellets
in horses used for breeding purposes, during pregnancy, or in lactating
mares has not been evaluated. The safety of PROTAZIL® (1.56%
diclazuril) Antiprotozoal Pellets with concomitant therapies in horses
has not been evaluated. For complete information, refer to the product
Protazil is sold exclusively to licensed veterinarians in 2- and
10-pound containers. Veterinarians interested in learning more about
Protazil, contact an Intervet/Schering-Plough Animal Health sales or
distributor representative. Horse owners should contact their